KENNESAW, Ga., Sept. 21, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has partnered with Affirmative Solutions, a national, leading distributor of spine, biologic and other medical products and devices to the U.S. Veteran’s Administration (“VA”) and Department of Defense (“DOD”) facilities.
A nationally established company, Affirmative Solutions is certified as a Service Disabled Veteran-Owned Small Business (SDVOSB) that is dedicated to meeting the needs of Medical Treatment Facilities (“MTF”) with a widely diverse range of quality medical and commercial products. Affirmative Solutions markets, sells and serves as a financial liaison to MTFs operated by the VA and the DOD, as well as, commercial healthcare facilities throughout the United States. Affirmative Solutions currently distributes products and devices to over 100 major VA, DOD and commercial facilities across the country.
Through the distribution agreement, the MiMedx wound care offering, Epifix®, can now be offered to all the MTFs serviced by Affirmative Solutions, who through its SDVOSB status, is a preferred supplier to all its government accounts. MiMedx currently markets four sizes of Epifix®, and all four sizes are included in the agreement with negotiated pricing established at competitive rates.
MiMedx Chairman and CEO, Parker H. “Pete” Petit, commented, “This agreement is a significant step in MiMedx offering its products and tissues into the VA and DOD by partnering with a well-established distributor in this space. MiMedx will have access to all of the MTFs served by Affirmative Solutions, including those operated by the VA and DOD, plus select commercial MTFs. A hallmark of Affirmative Solutions is their high quality standards for customer service, and we are very pleased to have a distribution partner that shares our passion for service excellence,” added Petit.
“We are very excited about our relationship with Affirmative Solutions,” said Bill Taylor, MiMedx President and COO. “They have done an extraordinary job in growing their business model. With the significant market potential of our tissue offerings, it is critical that we align with an organization such as Affirmative Solutions that can grow and expand to meet the fast-paced demands of the market.”
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix and CollaFix, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 35,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the potential impact of the Company’s agreement with Affirmative Solutions in establishing the MiMedx products and tissues in the VA and DOD; the impact of the Company’s access to the MTFs on the demand for the Company’s products and tissues; the market potential of the Company’s tissue offerings; and the ability of Affirmative Solutions to grow and expand to meet the demands of the market. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the anticipated demand for the Company’s products and tissues as a result of the agreement with Affirmative Solutions and the Company’s access to the MTFs does not materialize; that the market opportunities created by the agreement are below expectations; that the market potential for the Company’s products and tissues is less than anticipated; that Affirmative Solutions may not be able to grow and expand as anticipated; and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2010, and its most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.
